Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,
MedPage Today on MSN9h
McDonald Criteria Revisions Signal Shift Toward MS as a Biologically Based DiseaseThe revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...
For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...
AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - FR0010557264 ...
Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...
Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...
Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...
Jeeping for Multiple Sclerosis brings awareness and resources to the Heights ...
Medpage Today on MSN5d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse OutcomesHigher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...
A woman is making a name for herself as the first Floridian to complete a 21-mile swim across the North Channel, from Ireland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback